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Background: Diabetic ketoacidosis (DKA) is conventionally treated using a single
line for administration of ready-made dextrose and saline solutions for rehydration.
For some patients this results in poor control of plasma glucose, sodium, and
effective osmolality.
Objective: Management of pediatric DKA requires close monitoring and frequent
titration of fluids, electrolytes, and dextrose. Because there is no consensus on the
safest DKA protocol, treatment is challenging. We developed a novel treatment
protocol for DKA that allows precise titration of dextrose and of the plasma sodium
concentration and fluid volume by adjusting the infusion rates of three separate lines.
Methods: We conducted a retrospective single-center study of 60 consecutive
pediatric DKA patients (age 7 months to 16 years) treated in a tertiary hospital in
Turku, Finland. The first 26 patients were treated with the conventional and the
following 34 patients with the novel protocol. We collected and analyzed clinical and
laboratory data, timing of medical interventions and clinical outcomes from the
electronic patient record system.
Results: Plasma effective osmolality remained more stable when the patient was
treated according to the novel protocol than the conventional protocol (p < 0.001)
and plasma sodium levels were higher (p = 0.018). Recovery from acidosis was also
faster. Two patients on the conventional protocol needed intracranial pressure
monitoring and ventilator support, none on the novel protocol. There were no deaths
in either protocol.
Conclusions: Our novel protocol allows more precise control of the effective plasma
osmolality and appears to be as safe as the conventional protocol.
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Introduction
The incidence of type 1 diabetes among children aged 0–14 years in Finland is
57.6/100.000 – highest in the world (2). Most alarmingly, the incidence is increasing
globally, especially among the youngest children, those aged 0–4 years (3–5). For
children, diabetic ketoacidosis (DKA) is more detrimental than for adults (6). Mortality
among children with DKA is 0.15–0.3%, but if DKA-associated cerebral edema (CE)
is present, mortality rises to 20–25% (7). Since the subdural space of children is
narrower than of adults, the osmolytic balance in plasma needs to be controlled
stringently during rehydration (8). Also, other autoregulatory mechanisms are not as
well developed in children as in adults (7).
Management of DKA requires close monitoring and frequent titration not only of the
fluid replacement therapy, but also of the administration of electrolytes and dextrose.
DKA is treated by rehydration and, to normalize hyperglycemia, with insulin.
However, the timing of treatment and the composition of the rehydration solutions is
controversial (9,10). The consensus guidelines of the International Society for
Pediatric and Adolescent Diabetes (ISPAD) (11) recommend to initiate dextrose
infusion, when plasma glucose falls to approximately 14-17 mmol/L or sooner if the
rate of fall is very rapid. Furthermore, use of 5-12.5% dextrose may be necessary to
prevent hypoglycemia. Still, the range of fluid administration is wide, which leaves
patient-specific guidance ambiguous.
ISPAD acknowledge that the plasma sodium concentration should increase
throughout treatment for DKA. The sodium concentration of the rehydration solution
seems to be an independent factor influencing plasma sodium levels and, hence, the
effective osmolality of the plasma (12). Previous results suggest that keeping the
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effective osmolality stable is one of the most important factors affecting patient
outcome (13,14). Young age, new-onset diabetes and a prolonged duration of
symptoms have been associated with CE. Also a small, rather than a swift, increase
in the plasma sodium concentration during therapy and treatment included
administration of bicarbonate solution has been correlated with a higher incidence of
CE (11). Furthermore, mortality is lower when patients with DKA are treated with
isotonic instead of hypotonic solutions (12)(15).
Many hospitals have their own treatment practices for DKA, which makes it difficult
to compare the outcomes of DKA treatment across institutions and countries. Since
there is no consensus on the safest DKA protocol, treatment is challenging.
We conducted a retrospective study to evaluate the conventional one-line protocol
traditionally used in Turku University Hospital to our novel protocol consisting of
separate infusions of concentrated 50% dextrose, a balanced electrolyte solution,
hypertonic 3% saline and insulin. We hypothesized that meticulous titration of
dextrose, sodium and fluid volume by adjusting the infusion rates separately
improves patient outcome by better maintenance of the stability of the effective
plasma osmolality. Our aim was also to implement a more adaptable and flexible tool
for maintaining effective plasma osmolality. The primary outcome measure was
effective plasma osmolality and the secondary outcome measures were duration of
acidosis, plasma sodium, potassium, chloride and glucose levels, volume of




This retrospective study included all patients younger than 16 years who were
admitted because of DKA and were treated between January 1, 2013 and December
31, 2017 in the pediatric intensive care unit (PICU) at the Turku University Hospital,
Turku, Finland. Patients were identified consecutively from our electronic patient
record system (Centricity Critical Care Clinisoft 8.0, GE Electronics, Helsinki,
Finland) and Uranus (CGI, Montreal, Canada) by the ICD-10 code E10.1 (type 1
diabetes mellitus with ketoacidosis). We included the patients who fulfilled the criteria
for DKA by the ISPAD guidelines 2018: hyperglycemia (glucose >11mmol/L [>250
mg/dL]), venous pH <7.30 or serum bicarbonate <15 mmol/L, and ketonemia (blood
β-hydroxybutyrate ≥3 mmol/L) or moderate or severe ketonuria. Mild, moderate and
severe DKA were defined as pH <7.3 or HCO3 <15 mmol/L, pH <7.2 or HCO3 <10,
and pH <7.1 or HCO3 <5 mmol/L, respectively (11).
All patients who were diagnosed with DKA were transferred immediately from the
emergency room to the PICU and treatment started immediately with the DKA
protocol used at that time. Throughout the study, patients were treated by the same
physicians, nurses, pediatric intensive care specialists and endocrinologist
consultants in the PICU.
Recorded data
Age, height and weight of the patients were collected from the electronic patient
records. The total amount of insulin, fluids, dextrose, sodium, potassium and
chloride administered during DKA treatment in the PICU were recorded, as were
clinical data, timing of medical therapies and clinical outcomes.
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Appropriate analyses of pH, bicarbonate, base excess, glucose, sodium, potassium
and chloride were made with blood gas analyzer (ABL800 FLEX, Radiometer
Medical ApS, Brønshøj, Denmark) and recorded in the patient records from which
they were transferred for analysis of the data for this report.  Both the laboratory
measures and point of care tests were included in our analyses. The effective
plasma osmolality (POsmol) was calculated from plasma glucose (PGluc) and sodium
(PNa) levels using the equation: POsmol = PGluc + 2 x PNa. The following clinical data
were also recorded: somnolence, nausea, headache, pediatric Glasgow Coma Scale
(pGCS) score, cerebral edema, need for intracranial pressure measurement and
ventilation therapy.
Treatment protocols 
Both protocols were based on common guidelines and instructions by ISPAD (10).
The aim of both protocols was to maintain effective plasma osmolality stable during
the first 18 hours of treatment while steadily correcting dehydration, acidosis, plasma
glucose and electrolyte levels. In both protocols, a glucose decrease of no more than
3 mmol/L/h was considered optimal and glucose was not allowed to decrease under
a concentration of 10 mmol/L before ketosis was resolved.
The conventional treatment protocol (Protocol 1, Group 1) follows the practice of
using multiple ready-made dextrose and saline solutions to achieve an optimal total
solution concentration (Figure 1). We used 5% dextrose with 0.9% saline and 0–60
mmol/L potassium replacement in Protocol 1, depending on plasma potassium
levels. Insulin was administered intravenously at a rate of 0.075–0.1 IU/kg/h. If
plasma sodium decreased concomitantly with plasma glucose, causing a sharp
decrease in effective osmolality and patient showed symptoms of CE, hypertonic 3%
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saline infusion was administered at a rate of 0.1–1 mL/kg/h as judged by the
responsible physician.
Protocol 2 (Group 2) is a novel protocol developed at our institution.  It is based on
three separate infusions: 50% dextrose, a balanced electrolyte solution (BES,
Plasma-Lyte 148®, Baxter, Deerfield, IL, USA) and hypertonic 3% saline, each
adjusted individually through separate infusion pumps (Figure 1). An insulin infusion
(0.05 IU/kg/h) was started at the same time. 50% dextrose, infused together with
BES, was started at a low infusion rate to give the total concentration of 3.3%
dextrose. The infusion rate of dextrose was adjusted to the rate of plasma glucose
decline; e.g. in case of undesirably rapid glucose decrease, dextrose infusion rate
was increased according to guidelines set by our institution. Because 50% dextrose
is highly hyperosmolar, it was always infused alongside BES. Also, a safety protocol
was followed where all infusions were stopped during the time the infusions were
adjusted. Hypertonic 3% saline was infused only if the plasma sodium level did not
rise sufficiently during treatment to maintain effective osmolality. In practice, the
sodium concentration of the overall infusion was initially raised from 131 to at least
154 mmol/L initially, but if necessary, even higher. Potassium phosphate was added
to the BES at a standard concentration of 35 mmol/L after initial resuscitation to meet
the need of potassium and phosphate. Appropriate rates of the infused fluids were
documented in a spreadsheet program (written by the authors; Excel 2013,
Windows, Microsoft, U.S), which visualized the contents of each fluid used. The goal
of this protocol was to maintain effective plasma osmolality constant during the first
12–18 hours after which it was slowly allowed to decrease.
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Rehydration
Fluid resuscitation of the patient was started with 360 mL/m2/30 min under the
assumption that the patients were 7% dehydrated. If the patient still was after the
first fluid resuscitation hemodynamically unstable, the resuscitation was repeated in
both protocols. The resuscitation fluid was 0.9% saline in Protocol 1 and BES in
Protocol 2. The rate of the fluid replacement during rehydration in both protocols was
kept constant during the first two 6-hour periods after treatment start (during the first
6-hour period the infusion rate was 1800 mL/m2 and during the second 6-hour period
900 mL/m2). During the third and fourth 6-hour periods the infusion rate was 480 in
Protocol 1 and 600 mL/m2 in Protocol 2, respectively. If a patient needed all four 6-
hour treatment periods, the total infused volume was 4020 and 4260 mL/m2/24 h in
Protocols 1 and 2, respectively.
In both protocols, fluid loss via diuresis was replaced only when excessive diuresis
resulted in a negative fluid balance and slow correction of acidosis. Polyuria was
compensated with 5% dextrose and added electrolytes based on the urine analysis
in Protocol 1 and with BES in Protocol 2.
Statistical analyses
The sample size was based on previous experience in similar retrospective studies.
The primary outcome measure was effective osmolality at 18 hours after the start of
treatment. Secondary outcome measures were duration of acidosis, plasma sodium,
potassium, chloride and glucose levels, the amount of insulin and crystalloids infused
and neurological status. Data were evaluated for normality of distribution using probit
plots and Shapiro-Wilk’s W-test. The data was analyzed first as one group for
descriptive statistics, after which the patients were allocated into two treatment
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groups based on the DKA treatment protocol to analyze the effect of treatment
protocol. Continuous variables were compared with one-way ANOVA, while
categorical data was compared with the Kruskal-Wallis test. Data were log-
transformed prior to ANOVA analysis, but non-transformed results are reported.
Levene’s test for homogeneity of variances was used prior to ANOVA. The results
are expressed as mean values and SD, except for categorical and time-related
parameters that are reported as medians and interquartile range (IQR). The
statistical significance level was set at p < 0.05. R software (version 3.6.1) (16) and
ggplot2 (version 3.3.2)(17) were applied for statistical analysis and graphics.
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Results
There were no differences between the Groups 1 and 2 in demographic data nor
baseline laboratory values (Table 1). The evolution of primary and secondary
outcome measures and controllability of effective plasma osmolality is shown in
Figure 2. The laboratory measures showing the correction of acidosis (BE, HCO3
and pH) are shown in Figure 3. The amounts of infused fluids, electrolytes and
insulin are shown in Table 2 and in Figure 4.
Patients
The total number of patients who fulfilled the entry criteria over the five-year period
2013–2017 was 60. There were 26 consecutive patients in Group 1 and 34 in Group
2. DKA was mild in 12 (40%), moderate in nine (30%) and severe in nine (30%)
patients in Group 1, whereas DKA was mild in 17 (57%), moderate in eight (27%),
and severe in five (17%) patients in Group 2.
Controllability of effective plasma osmolality
In Group 1, the effective plasma osmolality (mean and SD) decreased from a
mean baseline value of 294 mosm/L (11.3) to 291 mosm/L (6.24) in 6 hours and to
288 mosm/L (6.81) in 12 hours. In Group 2, the corresponding figures were 295
mosm/L (11.9), 294 mosm/L (11.9) and 296 mosm/L (11.6).
In Group 1, the average (SD) plasma sodium was 134 (5.4) mmol/L at baseline,
137 mmol/L (2.84) at 6 hours and 138 mmol/L (3.35) at 12 hours. In Group 2, the
corresponding values were 135 mmol/L (4.46), 138 mmol/L (3.79) and 140 mmol/L
(4.18).
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The mean (SD) plasma glucose decreased in Group 1 from a baseline value of
24.3 mmol/L (6.32) to 17.8 mmol/L (5.63) in 6 hours and 13.7 mmol/L (6.0) in 12
hours. In Group 2 the corresponding values were 23.3 mmol/L (6.32), 18.0 mmol/L
(5.63) and 15.6 mmol/L (6.0) (Figure 3).
In Group 2, plasma sodium and osmolality levels remained significantly higher
throughout the treatment period than in Group 1 (p = 0.018 and p < 0.001,
respectively). During the treatment, plasma glucose decreased less from baseline
and exhibited less dispersion of values during the first 24 hours in Group 2 than in
Group 1 (Figure 2).
Resolution of acidosis
In Group 1, plasma bicarbonate increased from a mean (SD) baseline value of 13.1
mmol/L (3.78) to 16.7 mmol/L (3.98) in 6 hours and to 19.2 mmol/L (2.99) in 12
hours. In Group 2, the corresponding values were 11.7 mmol/L (3.31), 19.5 mmol/L
(3.57) and 21.9 mmol/L (2.39), at 0, 6 and 12 hours, respectively. In Group 1, the
base excess (BE) changed from a mean (SD) baseline value of -15.9 (13.9) to -9.8
(6.11) in 6 hours and to -6.46 (4.11) in 12 hours. In Group 2, BE the corresponding
values were -17.3 (5.16), -6.25 (4.33) and -3.15 (3.76).
In Group 1, pH changed from a mean (SD) baseline value of 7.20 (0.11) to 7.29
(0.06) in 6 hours and 7.34 (0.43) and 12 hours. In Group 2, the corresponding values
were 7.18 (0.12), 7.35 (0.06) and 7.38 (0.04) (Figure 3). One patient in Group 1
received sodium bicarbonate to treat acidosis, but in Group 2 no one needed it.
Total amounts of fluids and dextrose infused
Table 2 sums and Figure 4 shows the total amount of therapeutics administered to
the patients. In Group 2 the patients were infused 39% less insulin during the
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treatment period than in Group 1 (1.6 vs 0.9 IU/kg, 95% CI –1.028 to -0.256 IU/kg, p
= 0.003).
The total amount of fluids infused did not differ significantly between the two groups.
In Group 1 and Group 2, a mean (SD) of 147 (131) and 141 (79) mL/kg of fluids was
infused during treatment, respectively. The average total amount of fluids was
4128.00 and 4073.50 mL in Group 1 and Group 2, respectively (p = 0.773).
The level of acidosis affected the administered fluid volume. The patients in Group 1
and Group 2 received on average 104.2 vs 127.5 mL/kg of fluids in mild, 162.6 vs
133.3 mL/kg in moderate and 188.7 vs 173.3 mL/kg in severe acidosis, respectively.
Due to the small sample size, statistical inference was not assessed. The total
amount of dextrose administered did not differ between the groups. On average, the
patients in Group 1 received 8.9 (11.9) g/kg of dextrose and the patients in Group 2
received 7.4 (5.5) g/kg (p = 0.807).
Total amounts of electrolytes infused
The average (SD) amount of infused sodium was 15.7 (11.7) mmol/kg in Group 1
and 18.3 (9.7) mmol/kg in Group 2 (p = 0.033). The mean amount of potassium was
4.5 (4.5) and 5.0 (5.1) mmol/kg and that of chloride 15.5 (11.2) and 15.3 (10.1)
mmol/kg in Group 1 and 2, respectively. The amount of potassium and chloride
administered did not differ between the groups (p = 0.589 and 0.971, respectively).
Clinical outcome
All patients recovered from the DKA. Two patients in Group 1 needed ventilator
support due to worsening of neurological symptoms. The intracranial pressure of
these two patients was also monitored, and the intracranial pressure of one of them
was high (44 mmHg, reference <15 mmHg). In Group 2 intracranial pressure
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monitoring was not needed in any of the patients and neurological symptoms, when
present, were mild. One patient in Group 2 was sedated with dexmedetomidine to
treat anxiety. Plasma creatinine was monitored only once at the beginning of




We conducted a retrospective study of 60 consecutive pediatric patients treated at
our hospital to compare two protocols used to treat DKA. Our main interest was to
study the controllability of effective osmolality, but we were also interested in whether
there was a difference between the time it takes for acidosis to resolve and safety
matters. We have experienced previously that we need new tools to keep plasma
osmolality steady during the treatment. We hypothesized that more precise titration
of dextrose, sodium, and fluid volume by adjusting the infusion rates separately
could improve outcomes by providing more stability to the level of effective plasma
osmolality. 2-line and 3-line methods have been previously described in the literature
(18) (19), but this is the first time, to our knowledge, that all properties of the
infusions used to treat DKA are adjusted individually and precisely as desired.
Patient-specific needs may vary widely during treatment. To achieve an accurate
concentration, we used a spreadsheet pre-programmed with the contents of the
solutions to evaluate the effects of any changes we made to the concentrations of
the infusion solutions. The use of a more concentrated dextrose solution (50%)
made it easier to control and modify the concentration of the infused electrolytes.
Effective osmolality was maintained stable during the first 12 hours after treatment
start with the novel protocol (Protocol 2), but this was not the case with the
conventional protocol (Protocol 1) where the effective osmolality decreased steadily.
Protocol 2 resulted in better control of the effective plasma osmolality than Protocol 1
(Figure 2 and 3). It has been suggested that effective osmolality should remain
stable for approximately 15 hours from the start of treatment and then slowly decline
(14). If the effective osmolality is to remain unchanged, the factors affecting it, i.e.,
changes in plasma glucose and sodium, must be controlled carefully.
17
During treatment, the plasma glucose decreased more gradually on Protocol 2 than
Protocol 1, and there was less dispersion in the glucose concentration. Without
dextrose, plasma glucose levels fell steeply during the insulin infusion and this
resulted in unstable effective plasma osmolality levels in Protocol 1. In both
protocols, we used dextrose-containing infusions to manage the decrements in
plasma glucose concentrations. The amount of dextrose in Protocol 2 could be fine-
tuned to match the desired decrement rate of the plasma glucose concentration, but
in Protocol 1 the amount of dextrose was bound to the concentrations of the ready-
made dextrose solutions and did not fully meet the need for dextrose.
In Protocol 2, a hypertonic 3% saline infusion was added to the treatment of the
patients whose sodium levels did not rise sufficiently.  With hypertonic saline
infusion, the aim was to increase the plasma sodium concentration of the overall fluid
infusion from 131 to 154 mmol/L or even higher. This technique was usually effective
for controlling sodium levels, and, by the end of treatment, plasma sodium levels
were significantly higher on Protocol 2 than Protocol 1. In a previous study (12), a
too modest increase in the plasma sodium concentration reduces osmolality and CE
symptoms emerge concomitantly with reduced plasma glucose concentrations. On
Protocol 2, we recorded no signs of elevated intracranial pressure, but on Protocol 1
two patients showed signs of increased intracranial pressure and required invasive
intracranial pressure monitoring. None of the patients died.
Acidosis was corrected significantly faster on Protocol 2 than Protocol 1: the median
time for resolution of acidosis was 6 hours and 12 hours, respectively. On Protocol 2
the insulin infusion rate (usually 0.05 IU/kg/h) was lower than on Protocol 1 (0.1
IU/kg/h), and thus ketone elimination does not explain the difference in the time to
acidosis correction. Nor is faster recovery of lactate levels during rehydration
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probable, since the total amount of fluids infused did not differ between the groups.
The amount of chloride in the fluids used in the protocols was the same, but the
buffers (acetate, gluconate, and lactate) metabolized to bicarbonate were not: saline
in Protocol 1, BES in Protocol 2. Thus, BES might correct pH faster than chloride-
based fluids. This is, however, inconsistent with the results of the SPinK trial (20),
where the time to resolution of DKA was similar (14.5 h in BES and 16 h in the saline
group).  On the other hand, the total amount of fluids was lower than in our protocols.
The recent PECARN DKA Fluid Study did not find differences in the rate of mental
decline in patients whose dehydration was treated with fluids with different sodium
contents administered at different rates (21). This is in line with a previous report on
protocols using different tonicity and fluid volumes (22). The authors of neither study
reported data on effective osmolality and deterioration of pGCS values or brain
injury. Obviously, more studies are needed to establish the effect of sodium
concentration on maintenance of effective osmolality when treating DKA of pediatric
patients.
One of the strengths of our study is the comparability of the data. There were only
few non-protocol variables since both protocols have been followed in the same
hospital. The data were extracted from an electronic patient information system,
which allowed us to use accurate time points for laboratory values.
This study has the drawbacks of being retrospective in design.  Despite a relatively
small number of patients, significant differences were recorded. Also, the data were
unevenly distributed between the groups, with the number of mild DKA cases being
as high as severe and moderate. Some data series were incomplete, as expected for
a retrospective study: The exact time for ketone removal was not determined, pGCS
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was not recorded systematically and the length of stay (LOS) at the PICU was not
determined because the transfer to the pediatric ward after resolving of DKA
depends on non-protocol factors such as the time of day and degree of occupancy of
the pediatric wards.
In summary, we present a novel protocol for treating DKA appears to be significantly
better than the conventional protocol for controlling the effective osmolality of
plasma. Acidosis resolution takes only half the time, and this substantially shortens
the duration of treatment. Benefits in terms of reduced morbidity are difficult to
assess – this would require a much bigger number of patients – but might be
substantial if the novel protocol would be used widely. Improved acidosis clearance
seems to reflect easy adaptability of the novel protocol; it meets the patient’s
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Table 1 - Demography and baseline laboratory values during admission of patients
treated with the conventional and new protocol.
Data are shown as means (SD), except for age and pH, which are given as median








Age (years) 11.1 (1.0, 15.7) 12.0 (0.67, 16.4) 0.363
Weight (kg) 39.5 (19.6) 42.1 (21.6) 0.756
P-glucose (mmol/L) 24.3 (6.32) 23.3 (6.32) 0.485
P-sodium (mmol/L) 135 (4.9) 135 (4.5) 0.438
P-osmolality (mosm/L) 294 (11.3) 295 (11.9) 0.704
P-pH 7.22 (6.90, 7.29) 7.20 (6.88, 7.30) 0.340
P-bicarbonate (mmol/L) 13.1 (3.8) 11.7 (3.31) 0.534
P-OHBut (mmol/L) 6.6 (1.8) 6.2 (2.1) 0.423
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Table 2 - Total amounts of fluids, insulin, glucose and electrolytes infused during the






Infusion fluids (mL/kg) 113.0 [90.2, 149.3] 120.1 [85.2, 162.9] 0.773
Insulin (IU/kg) 1.6 [1.2, 2.2] 0.9 [0.6, 1.4] 0.003
Glucose (g/kg) 6.5 [4.1, 8.8] 5.6 [3.6, 10.4] 0.807
Sodium (mmol/kg) 10.8 [8.3, 16.4] 14.8 [11.3, 23.1] 0.033
Potassium (mmol/kg) 2.7 [1.6, 5.0] 3.4 [2.0, 7.1] 0.589
Chloride (mmol/kg) 11.9 [8.5, 16.4] 12.2 [8.2, 16.7] 0.971
Data are shown as as median and interquartile range. IU, international units.
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Figure 1. Treatment protocols. Protocol 1 (left). Dextrose and saline were infused
with varying concentrations as shown (*). Concentrations were adjusted every six
hours, but also during each period if necessary (in blue). However, the relative
proportions of saline (2/3) and 10% dextrose (1/3) volumes were kept constant.
Potassium concentration of the replacement fluid varied from 0 to 60 mmol/L based
on plasma potassium levels. In addition, constant insulin infusion of 0.1 IU/kg was
administered until plasma glucose decreased below 15 mmol/L, after which the rate
was adjusted to 0.075 IU/kg. Renal losses were replaced with 5% dextrose
supplemented with sodium and potassium, which were adjusted based on urine
analysis. DEX, dextrose. Protocol 2 (right): Dextrose, a balanced electrolyte solution
(BES, Plasma-Lyte 148®, Baxter, Deerfield, IL, USA) and hypertonic 3% saline were
each adjusted individually through separate infusion pumps. The proportion of BES
and 50% dextrose were adaptively adjusted according to the plasma glucose levels
and effective osmolality values. If necessary, the sodium concentration of the
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solution was increased with 3% NaCl-solution. Constant insulin infusion of 0.05 IU/kg
was administered throughout the treatment. 35 mmol/L potassium was added to
BES. Replacement of renal losses was performed by increasing the rate of BES
infusion. Infusion rates and total volumes during each period are shown in the middle
(in orange). In Protocol 2, the total volume and infusion rate of the 12–24-hr period
was 600 mL/m2.
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Figure 2. Individual measured plasma glucose, sodium and osmolality (mosm/L)
levels during the study. Each gray line represents one patient, and the blue line
represents the LOESS-smoother. Upper panel (A) shows Group 1 and lower panel
(B) Group 2. LOESS, locally estimated scatterplot smoothing. In Group 2, plasma
sodium and osmolality levels were significantly higher during the whole treatment
period than in Group1 (p= 0.018 and p=<0.001, respectively).
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Figure 3. Time course of plasma glucose, sodium and osmolality (mosm/L) in Group
1 (gray) and Group 2 (orange) during the first 12 hours after start of treatment of
DKA. Box plots show the median and 25–75th percentiles, and the whiskers show
the minimum and maximum.
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Figure 4. Total amounts of electrolytes and fluids administered during the study in
Group 1 (grey) and Group 2 (orange). Box plots show the median and 25–75th
percentiles, and the whiskers show the minimum and maximum.
